Study Title: A Phase 2 Study of Mecbotamab Vedotin (BA3011) Alone and in Combination with Nivolumab in Adult Patients with Metastatic Non Small Cell Lung Cancer (NSCLC) Who Had Prior Disease Progression on or Are Intolerant to a PD 1/L 1, EGFR, or ALK Inhibitor
This trial is closed to accrual. For general questions, please contact the Clinical Trials Office.